Citation: Wanda C Reygaert. An overview of the antimicrobial resistance mechanisms of bacteria[J]. AIMS Microbiology, 2018, 4(3): 482-501. doi: 10.3934/microbiol.2018.3.482
[1] | Hasan Zulfiqar, Rida Sarwar Khan, Farwa Hassan, Kyle Hippe, Cassandra Hunt, Hui Ding, Xiao-Ming Song, Renzhi Cao . Computational identification of N4-methylcytosine sites in the mouse genome with machine-learning method. Mathematical Biosciences and Engineering, 2021, 18(4): 3348-3363. doi: 10.3934/mbe.2021167 |
[2] | Jianhua Jia, Mingwei Sun, Genqiang Wu, Wangren Qiu . DeepDN_iGlu: prediction of lysine glutarylation sites based on attention residual learning method and DenseNet. Mathematical Biosciences and Engineering, 2023, 20(2): 2815-2830. doi: 10.3934/mbe.2023132 |
[3] | Jianhua Jia, Yu Deng, Mengyue Yi, Yuhui Zhu . 4mCPred-GSIMP: Predicting DNA N4-methylcytosine sites in the mouse genome with multi-Scale adaptive features extraction and fusion. Mathematical Biosciences and Engineering, 2024, 21(1): 253-271. doi: 10.3934/mbe.2024012 |
[4] | Jianhua Jia, Lulu Qin, Rufeng Lei . DGA-5mC: A 5-methylcytosine site prediction model based on an improved DenseNet and bidirectional GRU method. Mathematical Biosciences and Engineering, 2023, 20(6): 9759-9780. doi: 10.3934/mbe.2023428 |
[5] | Pingping Sun, Yongbing Chen, Bo Liu, Yanxin Gao, Ye Han, Fei He, Jinchao Ji . DeepMRMP: A new predictor for multiple types of RNA modification sites using deep learning. Mathematical Biosciences and Engineering, 2019, 16(6): 6231-6241. doi: 10.3934/mbe.2019310 |
[6] | Eric Ke Wang, liu Xi, Ruipei Sun, Fan Wang, Leyun Pan, Caixia Cheng, Antonia Dimitrakopoulou-Srauss, Nie Zhe, Yueping Li . A new deep learning model for assisted diagnosis on electrocardiogram. Mathematical Biosciences and Engineering, 2019, 16(4): 2481-2491. doi: 10.3934/mbe.2019124 |
[7] | Keruo Jiang, Zhen Huang, Xinyan Zhou, Chudong Tong, Minjie Zhu, Heshan Wang . Deep belief improved bidirectional LSTM for multivariate time series forecasting. Mathematical Biosciences and Engineering, 2023, 20(9): 16596-16627. doi: 10.3934/mbe.2023739 |
[8] | Hui Li, Xintang Liu, Dongbao Jia, Yanyan Chen, Pengfei Hou, Haining Li . Research on chest radiography recognition model based on deep learning. Mathematical Biosciences and Engineering, 2022, 19(11): 11768-11781. doi: 10.3934/mbe.2022548 |
[9] | Honglei Wang, Wenliang Zeng, Xiaoling Huang, Zhaoyang Liu, Yanjing Sun, Lin Zhang . MTTLm6A: A multi-task transfer learning approach for base-resolution mRNA m6A site prediction based on an improved transformer. Mathematical Biosciences and Engineering, 2024, 21(1): 272-299. doi: 10.3934/mbe.2024013 |
[10] | Guanghua Fu, Qingjuan Wei, Yongsheng Yang . Bearing fault diagnosis with parallel CNN and LSTM. Mathematical Biosciences and Engineering, 2024, 21(2): 2385-2406. doi: 10.3934/mbe.2024105 |
Since the beginning of the HIV epidemic, it is estimated that 75 million people have been infected with HIV and 36 million have died [40]. HIV spans the globe, affecting every country, although some have fared worse than others. This is especially apparent in sub-Saharan Africa, with an estimated 5% of all adults infected [40]. HIV is not restricted to certain age groups, and, despite prevention programs and awareness campaigns, HIV incidence continues to increase, particularly amongst men who have sex with other men (MSM).
Fortunately, there have been numerous medical advancements since AIDS and HIV were defined in 1982-85. In 1986, the first antiretroviral therapy (ART) was introduced to prolong the life of individuals affected with HIV and reduce its spread. This changed the perspective of HIV to that of a chronic disease. Questions are now raised as to why the incidence rate continues to increase amongst certain population groups. Numerous surveys attempt to explain an individuals' reasoning, but the results have been varied, showing evidence of increased risky behaviour as well as decreased or no change in behaviour. [12,22,28,32]. The imminence of prophylactic HIV vaccines (such as one being developed at The University of Western Ontario [39]) would have an enormous impact worldwide, but also raises some new interesting questions, chief among them being how to asses its impact on individuals contemplating whether to engage in casual sex, specifically in unprotected casual sex.
Population models have been useful in understanding and predicting the spread of HIV [20,36,18,31,19]. To better understand how one individual can affects change at population level game-theoretical models have been used [30,33] These models illuminate a feedback mechanism where individual's choices may affect the population, which in turn affect the choices an individual is likely to make.
Game theory dates back to late 1940s with the works of von Neumann and Morgenstern [37] and later those of Nash [26] in the early 1950s. A game is a mathematical framework to describe decision-making by individuals engaged in competitive situations, where they can behave noncooperatively or cooperatively. Noncooperative game theory is nowadays widely used in applied areas such as economics, engineering, operations research, evolutionary biology and social sciences (psychology and cognitive sciences) see [4,15,16] and many references therein. The question of existence and computation of Nash strategies for a given game can be tackled with various methods, such as the reaction-curves method, optimization techniques, variational inequalities, computational methods (such as genetic algorithms, evolutionary computation), or a replicator-dynamics equilibrium, etc. [4,10,21,0,11].
Generalized Nash games (GN) with finite dimensional strategy sets were first studied by Arrow and Debreu in [1], followed by [29,23,34,27], with a recent review in [14]. The formulation of the generalized Nash game as a variational inequality problems dates back to Bensoussan [5], while [34] gives first equivalence results for finite-dimensional GN games and quasivariational inequalities.
In this paper, we model casual (sexual) encounters as a noncooperative generalized Nash game between 2, 3, or 4 players, where each player's HIV status is known to both one's self, and to the player they choose to interact with. We do not model in this paper a population-level transmission process. All players have personal preferences ranked in utility of unprotected and protected sex outcomes, and they are given expected utilities of the casual encounter, depending on possible outcomes: unprotected sex outcome (
In our previous work on the topic, we modelled a similar setup of casual encounters with an agent-based model of the population [33,35], and we analyzed how groups can emerge from coevolution of HIV spread with partner choices and risk perception, where we also assumed that a player's true HIV status is only known to themselves. In this model, unlike our previous simulation-based work, we construct a theoretical model to identify and analyze Nash equilibria with respect to the decisions players make. This allows us to better understand: a) the impact of personal preferences for unprotected sex; and b) the impact of heterogeneity of players (division in age groups) and initial HIV age composition both in presence and absence of a prophylactic vaccine.
To the best of our knowledge, modelling HIV transmission with age-stratified multiplayer GN games models is absolutely novel in the literature. There are a handful of examples of multiplayer GN games in applied problems (the River Basin problem, electricity markets [25], cap-and-trade agreements [14], voluntary vaccination models [11]), so our work here is unique in pushing the boundaries of modelling using GN games.
The structure of the paper is as follows: In Section 2, we present a 2-player game while in Section 3 we formulate the multiplayer games of casual encounters between players in age groups. Throughout, we investigate the sensitivity of players' Nash strategies and of HIV transmission when changes in utility rankings, efficacy of prophylactic treatment and group-specific initial HIV age composition are taken into account. We close with a few conclusions and future work.
In general, a multiplayer game involves a finite number of players, denoted here by
Definition 2.1. Assume each player is rational and wants to maximize their payoff. Then a Nash equilibrium is a vector
$\forall i, \, \, f_{i}(x_{i}^{*}, x_{-i}^{*}) \geq f_{i}(x_{i}, x_{-i}^{*}), \, \forall x_i\in S_i$ |
where
For several decades, there exists, in the game theoretic literature, the concept of a generalized Nash (GN) game [1,29], which in brief is a game such as above, where however each player's strategy set
In this paper, we need to use the framework of GN theory, as our player interactions lead to casual sexual encounters in a closed population, thus the encounters have to obey a counting rule from both an
There are results asserting existence of generalized Nash equilibria for the type of games we model (see for instance [13,34,29] and references therein). One such approach is that of finding a small subset of solutions of a GN game by reformulating the GN game into a variational problem as below in Definition 2.2. Once the Ⅵ is proven to have solutions, computational methods are employed to find its solution set.
Definition 2.2. Given a set K
$\langle F(x^*), y-x^*\rangle \geq 0, \, \, \forall y\in K.$ |
The existence of a solution to the Ⅵ problem in Definition 2.2 can be shown in many mathematical contexts (see [24]) but, specifically for our cases here, we use the results in [13]. Specifically, we solve for generalized Nash strategies of players where
To solve the Ⅵ problem we compute its solution set as the set of critical points of a projected dynamical system (see [2,8]) given by
$\frac{dx}{d\tau}=P_{T_K(x(\tau))}(F(x(\tau))), \, \, x(0)\in K, $ | (1) |
where
It is known that the system (1) is well-defined if
Let us consider now a casual encounter between two individuals from a general population of individuals aged 15 and over. A player can have one of two statuses: HIV negative (
Utility ranking of preferences of each player is given based on the HIV status of the individual they might engage with, which is considered known to them, as well as based on the type of sexual outcome they may find themselves in, namely
Specifically, we assign as a numerical value for the utility of a sexual encounter the range of
Let us define the expected utilities for
$ E_{-}^{1} = \rho [x_{-}^{1} USE(+, -) + (1-x_{-}^{1} ) PSE( +, -)]\text { and } $ |
$ E_{+}^{1} = \rho [x_{+}^{1} USE(+, +) + (1-x_{+}^{1} ) PSE( +, +)] $ |
where
Then the overall expected utility of the encounter for
$E^{1} (x^1_{-}, x^1_+)= \epsilon_{+}E_{-}^{1} + (1-\epsilon_+) E_{+}^{1}.$ |
Similarly, for
$ E_{-}^{2} = \rho [x_{-}^{2} USE(-, -) + (1-x_{-}^{2} ) PSE(-, -)], $ |
$ E_{+}^{2} = \rho [x_{+}^{2} USE(-, +) + (1-x_{+}^{2} ) PSE(-, +)]. $ |
$\text{ Thus } E^{2} (x^2_{-}, x^2_+)= \epsilon_+ E_{-}^{2} + (1-\epsilon_+) E_{+}^{2}.$ |
Now let us recall that
$ \epsilon_{+} = \epsilon_{+}(0) + [x_{-}^{1} \epsilon_{+}(0) + x_{+}^{2} \epsilon_{-}(0)] \tau \label{eqn:3} $ | (2) |
where
Last but not least, we need to make sure that the number of possible sexual encounters that lead to transmission is the same whether counted from the
$ \epsilon_-\sum\limits_{i\in HIV_-}x^i_+=\epsilon_+\sum\limits_{i\in HIV+} x^i_- \Leftrightarrow (1-\epsilon_+)x^2_+=\epsilon_+ x^1_-, $ |
with
Players
$K:=\{S_{1}\times S_{2}\mid (1-\epsilon_+)x^2_+=\epsilon_+ x^1_-\}$ |
where
$S_{i}=\{x^{i}=(x^i_-, x^i_+) \in [0,1]^2, \, 0\leq x^i_-+x^i_+\leq 1, \, i=1, 2\}.$ |
Due to expression (2) we see that these utilities have actual dependencies on the other player's choices, so our model is a 2-player game with nonlinear payoffs.
At this stage, a discussion of parameter values we define as our ''base case scenario'' throughout the rest of the manuscript is needed. We outlined above our starting assumptions on the utility ranking values for
The base values used in our simulations, unless otherwise noted, are listed in Table 1.
Utility for USE | Utility for PSE | Range | ||
HIV+ | HIV+ | | | |
HIV+ | HIV- | | | |
HIV- | HIV+ | | ||
HIV- | HIV- | |
In general, it is expected that a Nash game will have multiple equilibria. We took a numerical approach to investigate the type of Nash equilibria we get in the game above. We first set the rest of our game parameters as described in Table 2 below. We then vary the initial conditions of the game reformulated as in equation (1), using experiments with uniformly distributed points from
Term | Definition | Baseline value | Range |
Probability of HIV spread from an | 0.02 | - | |
Initial proportion of | 0.05 | 5% of population | |
Initial proportion of | 0.95 | 95% of population |
In the next section, we investigate the sensitivity of these results with respect to changes in utilities for casual sex with players of opposite status.
In this section we are interested in investigating the effects of varying base utilities on the equilibrium strategies of both players to have unprotected sex in a casual encounter, namely on
We see a change in the equilibrium solution for both
We extend next the 2-player game presented in Section 2.2 to a multiplayer game, to capture interactions between players belonging to different age groups, as a possibly important factor in HIV transmission [7]. We consider here a population with 5 age cohorts, 15-20, 20-30, 30-40, 40-50 and 50+. Age group 1 (
A game is defined by choosing one
Let us denote by
$P_{1}\;\text{ in}\; game_i\; \text{belongs to}\; G_i.$ |
We assume first that
Finally, each age group has a differing activity parameter
$E^i:=\epsilon_+E^i_+(x)+(1-\epsilon_+)E^i_-(x), \, \forall i\in\{1, 2, 3\}.$ |
We start by setting up the game concerning age cohort 15-20, where we choose
We define their expected utilities as:
$ E_{-}^{1} = \rho_{1} \Big[(x^{1}_{1-} + x^{1}_{2-}) USE(+, -) + (1-(x^{1}_{1-} + x^{1}_{2-})) PSE( +, -)\Big] $ |
$ E_{+}^{1} = \rho_{1} \Big[( x^{1}_{1+} ) USE(+, +) + (1-x^{1}_{1+}) PSE( +, +)\Big] $ |
Then
Similarly for
$ E_{-}^{j} = \rho_{j-1} \Big[(x^{j}_{1-} + x^{j}_{2-}) USE(-, -) + (1-(x^{j}_{1-} + x^{j}_{2-})) PSE(-, -)\Big] $ |
$ E_{+}^{j} = \rho_{j-1} \Big[( x^{j}_{1+}) USE(-, +) + (1-x^{j}_{1+}) PSE(-, +)\Big] $ |
Each player strategies have to satisfy (
As a consequence of the interaction between players, the fractions of
$ \epsilon^{G_1}_{+} (game_1)= \epsilon^{G_1}_{+}(0) + \tau\Big[x_{1-}^{1} \epsilon^{G_1}_{+}(0) +x_{1+}^{2} \epsilon^{G_1}_{-}(0) \Big], \, \text{ and } $ |
$ \epsilon^{G_2}_{+} (game_1)= \epsilon^{G_2}_{+}(0) + [x_{2-}^{1} \epsilon^{G_1}_{+}(0) + x_{1+}^{3} \epsilon^{G_2}_{-}(0)] \tau $ |
Then we compute
$\displaystyle{\epsilon_+(game_1):=\sum\limits_{i=1}^5\epsilon_+^{G_i}(game_1)}.$ | (3) |
Last but not least, we need to impose the shared constraint that the number of possible sexual encounters that lead to transmission is the same when counted from each of the
$ (1-\epsilon_+(game1))(x^2_{1+}+x^3_{1+})=\epsilon_+(game1) (x^1_{1-}+x^1_{2-}), $ |
with
We investigate uniqueness of solutions for the generalized Nash equilibrium strategies computed as in Section 2.2. Figure 3 shows a non-unique Nash point while varying initial conditions of system (1). We ran 100 simulations each starting with 50 uniformly distributed initial values and the compiled results are always as in Figure 3. As expected, the equilibrium strategies are not unique, however, the equilibrium strategies for players engaging in USE with players of opposite status (namely
Similar to studying the 2-player game, we study the effects of varying
We know from our previous section that equilibrium strategies found for this game are not unique, thus initial conditions for the computation of equilibrium strategies under varying parameters are important. In order to derive our analysis, we use as initial conditions one of the equilibrium points computed in the subsection above:
$\underline{x}^*=\Big((0, 1, 0), (0.6369, 0, 0.3631), (0.62, 0, 0.38)\Big), $ | (4) |
relying on the fact that all equilibrium strategies for players engaging in USE with players of opposite status in the baseline scenario are 0. The new equilibrium strategies pictured above are:
$\underline{x}^*=\Big((0.5, 0, 0.5), (0.62, 0.02, 0.36), (0.62, 0, 0.38)\Big).$ |
Figure 4 shows more refined results than those in the 2-player scenario. Choices for
We describe next the 4-player game arising from choosing for instance
We denote
$P_1:\, \, \underline{0}\leq (x^{1}_{1-}, x^1_{2-}, x^1_{3-}, x^1_{2+})\leq \underline{1}\text{ s.t} x^{1}_{1-}+x^1_{2-}+x^1_{3-}+x^1_{2+}=1$ |
$P_2:\, \, \underline{0}\leq (x^{2}_{1-}, x^2_{2-}, x^2_{2+})\leq \underline{1}\text{ s.t. }x^{2}_{1-}+x^2_{2-}+x^2_{2+}=1$ |
$P_3:\, \, \underline{0}\leq (x^{3}_{1-}, x^3_{2-}, x^3_{3-}, x^3_{2+})\leq \underline{1}\text{ s.t. }x^{3}_{1-}+x^3_{2-}+x^3_{3-}+x^3_{2+}=1$ |
$P_4:\, \, \underline{0}\leq (x^4_{2-}, x^4_{3-}, x^4_{2+})\leq \underline{1}\text{ s.t. }x^4_{2-}+x^4_{3-}+x^4_{2+}=1$ |
The expected utilities for these individuals are listed below, starting with
$ E_{-}^{1} = \rho_{2} \Big[(x^{1}_{1-} + x^{1}_{2-} + x^{1}_{3-}) USE(+, -) + (1-(x^{1}_{1-} + x^{1}_{2-} + x^{1}_{3-})) PSE(+, -)\Big] $ |
$ E_{+}^{1} = \rho_{2} \Big[x^{1}_{2+} USE(+, +) + (1-x^{1}_{2+}) PSE(+, +)\Big] $ |
Similarly for
$ E_{-}^{2} = \rho_{1} \Big[(x^{2}_{1-} + x^{2}_{2-})USE(-, -) + (1-(x^{2}_{1-} + x^{2}_{2-})) PSE(-, -)\Big] $ |
$ E_{+}^{2} = \rho_{1} \Big[x^{2}_{2+} USE(-, +) + (1-x^{2}_{2+}) PSE(-, +)\Big] $ |
For
$ E_{-}^{3} = \rho_{2} \Big[(x^{3}_{1-} + x^{3}_{2-} + x^{3}_{3-}) USE(-, -) + (1-(x^{3}_{1-} + x^{3}_{2-} + x^{3}_{3-})) PSE(-, -)\Big] $ |
$ E_{+}^{3} = \rho_{2} \Big[x^{3}_{2+} USE(-, +) + (1-x^{3}_{2+}) PSE(-, +)\Big] $ |
Finally, for
$ E_{-}^{4} = \rho_{3} \Big[(x^{4}_{2-} + x^{4}_{3-})USE(-, -) + (1-(x^{4}_{2-} + x^{4}_{3-})) PSE(-, -)\Big] $ |
$ E_{+}^{4} = \rho_{3} \Big[x^{4}_{2+} USE(-, +) + (1-x^{4}_{2+}) PSE(-, +)\Big] $ |
As a result of interactions allowed in this game, the fraction of the infected individuals changes in groups 1, 2, 3 (note that
$ \epsilon^{G_j}_{+} (game_2)= \epsilon^{G_j}_{+}(0) + \tau\Big[x_{1-}^{j} \epsilon^{G_2}_{+} (0) +x_{2+}^{j+1} \epsilon^{G_j}_{-}(0) \Big], j\in\{1, 2, 3\} $ |
hen we compute
$\displaystyle{\epsilon_+(game_2):=\sum\limits_{i=1}^5\epsilon_+^{G_i}}.$ | (5) |
Last but not least, we need to impose the shared constraint that the number of possible sexual encounters that lead to transmission is the same when counted from each of the
$ (1-\epsilon_+(game2))(x^2_{2+}+x^3_{2+}+x^4_{2+})=\epsilon_+(game2) (x^1_{1-}+x^1_{2-}+x^1_{3-}), $ |
with
We again investigate uniqueness of solutions as we did in Section 2.2. Figure 5 shows non-unique Nash points while varying initial conditions of (1). We ran 100 simulations each starting with 50 uniformly distributed initial values and the compiled results are always as in Figure 5. As expected, the equilibrium strategies are not unique, however, the equilibrium strategies for players engaging in US with players of opposite status (namely
Similar to studying the 2-player and 3-player games, we vary
$\underline{x^*}=\Big((0, 0, 0, 1), (0.2799, 0.7201, 0), (0.3174, 0.3651, 0.3175, 0), (0.5339, 0.4661, 0)\Big), $ | (6) |
relying on the fact that all equilibrium strategies for players engaging in USE with players of opposite status in the baseline scenario are 0.
Figure 6 shows results similar to the 3-player scenario, where
The impact on the infection levels from such a game alone is shown to have an increasing direction. The infected fraction in the population (lower left panel of Figure 6) increases from the baseline value of 0.05% to
Recall that by
As we have stated in previous sections, in both analyses of
In this section we investigate implementing a theoretical prophylactic vaccine within the population, with efficacy
1This is an assumption only; treatment optimism can in fact increase HIV transmission, as we show in [35].
The population sizes are adjusted to fit
We investigate what impact these changes have on HIV transmission if
$\text{ game 1: } P_2\in G_1 \;\text{is}\; HIV- \text{vaccinated}, \, P_3\in G_2 \;\text{ is}\; HIV- \text{unvaccinated} $ |
$\text{game 2: } P_2\in G_1 \;\text{ is}\; HIV- \text{vaccinated}, \, P_3, P_4 \;\text{ are}\; HIV- \text{unvaccinated}.$ |
Games 3, 4, 5 do not involve players in
Results presented are dependent on varying the vaccine efficacy
The increase in
The previous sections outlined a one-off casual sexual encounters game for 2, 3 and 4 player variations dependent on status and age. Our most interesting conclusions are that preferences of
We showed that generalized Nash equilibria exist and can be computed for these types of games. Moreover, we demonstrated the sensitivity of GN equilibria with respect to varying players' utilities of unprotected sex with partners of opposite
As we expanded from 2-player to 3-and 4-player games, we in fact refined the interactions among the individuals in a population, previously regarded as one-on-one positive-negative outcomes. Given that the sizes of groups and activity parameter values matter, we saw that the increase in transmission due to a single instance of a 3-player or a 4-player game is smaller than in a 2-player game. However, the biggest contributing factor in changing HIV transmission is found to be due to the
We need to stress again here that the value of this modelling framework depends on the initial conditions of a population under observation, especially in the case of multiplayer groups. Moreover, knowing specific equilibrium strategies within the population of players can lead to sensitivity analyses having these specific equilibrium strategies as initial values. Last but not least, the fact that mathematically a generalized Nash game has in fact sets of equilibria gives strength to this modelling paradigm, in the sense that differing initial conditions in a players' population can give rise to different outcomes, which seems more appropriate to model real life encounter outcomes.
As future work, it would be interesting to include incorporation of ART for
This work has been funded by the National Science and Engineering Research Council of Canada. The authors gratefully acknowledge this support.
The authors would like to thank the anonymous referees for their excellent suggestions that led to a clearer presentation of our work. It is through their suggestions that we have come to realize the naturally arising shared constraint which pushed our models into the generalized Nash game applications presented here.
[1] | World Health Organization (2014) World Health Statistics 2014. |
[2] | World Health Organization (2015) Global action plan on antimicrobial resistance. |
[3] |
Griffith M, Postelnick M, Scheetz M (2012) Antimicrobial stewardship programs: methods of operation and suggested outcomes. Expert Rev Anti-Infe 10: 63–73. doi: 10.1586/eri.11.153
![]() |
[4] |
Yu VL (2011) Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis 11: 248–252. doi: 10.1016/S1473-3099(11)70005-6
![]() |
[5] | Goossens H (2009) Antibiotic consumption and link to resistance. Clin Microbiol Infec 15 3:12–15. |
[6] |
Pakyz AL, MacDougall C, Oinonen M, et al. (2008) Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 168: 2254–2260. doi: 10.1001/archinte.168.20.2254
![]() |
[7] |
Tacconelli E (2009) Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis 22: 352–358. doi: 10.1097/QCO.0b013e32832d52e0
![]() |
[8] |
Landers TF, Cohen B, Wittum TE, et al. (2012) A review of antibiotic use in food animals: perspective, policy, and potential. Public Health Rep 127: 4–22. doi: 10.1177/003335491212700103
![]() |
[9] | Wegener HC (2012) Antibiotic resistance-Linking human and animal health, In: Improving food safety through a One Health approach, Washington: National Academy of Sciences, 331–349. |
[10] | Centers for Disease Control and Prevention (CDC) (2013) Antibiotic resistance threats in the United States, 2013, U.S, Department of Health and Human Services, CS239559-B. |
[11] |
Maragakis LL, Perencevich EN, Cosgrove SE (2008) Clinical and economic burden of antimicrobial resistance. Expert Rev Anti-Infe 6: 751–763. doi: 10.1586/14787210.6.5.751
![]() |
[12] |
Filice GA, Nyman JA, Lexau C, et al. (2010) Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Cont Hosp Ep 31: 365–373. doi: 10.1086/651094
![]() |
[13] |
Hübner C, Hübner NO, Hopert K, et al. (2014) Analysis of MRSA-attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol 33: 1817–1822. doi: 10.1007/s10096-014-2131-x
![]() |
[14] |
Macedo-Viñas M, De Angelis G, Rohner P, et al. (2013) Burden of methicillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. J Hosp Infect 84: 132–137. doi: 10.1016/j.jhin.2013.02.015
![]() |
[15] |
Pakyz A, Powell JP, Harpe SE, et al. (2008) Diversity of antimicrobial use and resistance in 42 hospitals in the United States. Pharmacotherapy 28: 906–912. doi: 10.1592/phco.28.7.906
![]() |
[16] |
Sandiumenge A, Diaz E, Rodriguez A, et al. (2006) Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemoth 57: 1197–1204. doi: 10.1093/jac/dkl097
![]() |
[17] |
Wood TK, Knabel SJ, Kwan BW (2013) Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79: 7116–7121. doi: 10.1128/AEM.02636-13
![]() |
[18] |
Keren I, Kaldalu N, Spoering A, et al. (2004) Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230: 13–18. doi: 10.1016/S0378-1097(03)00856-5
![]() |
[19] | Coculescu BI (2009) Antimicrobial resistance induced by genetic changes. J Med Life 2: 114–123. |
[20] |
Martinez JL (2014) General principles of antibiotic resistance in bacteria. Drug Discov Today 11: 33–39. doi: 10.1016/j.ddtec.2014.02.001
![]() |
[21] |
Cox G, Wright GD (2013) Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol 303: 287–292. doi: 10.1016/j.ijmm.2013.02.009
![]() |
[22] |
Fajardo A, Martinez-Martin N, Mercadillo M, et al. (2008) The neglected intrinsic resistome of bacterial pathogens. PLoS One 3: e1619. doi: 10.1371/journal.pone.0001619
![]() |
[23] |
Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417–433. doi: 10.1128/MMBR.00016-10
![]() |
[24] | Reygaert WC (2009) Methicillin-resistant Staphylococcus aureus (MRSA): molecular aspects of antimicrobial resistance and virulence. Clin Lab Sci 22: 115–119. |
[25] |
Blázquez J, Couce A, Rodríguez-Beltrán J, et al. (2012) Antimicrobials as promoters of genetic variation. Curr Opin Microbiol 15: 561–569. doi: 10.1016/j.mib.2012.07.007
![]() |
[26] |
Chancey ST, Zähner D, Stephens DS (2012) Acquired inducible antimicrobial resistance in Gram-positive bacteria. Future Microbiol 7: 959–978. doi: 10.2217/fmb.12.63
![]() |
[27] | Mahon CR, Lehman DC, Manuselis G (2014) Antimicrobial agent mechanisms of action and resistance, In: Textbook of Diagnostic Microbiology, St. Louis: Saunders, 254–273. |
[28] |
Blair JM, Richmond GE, Piddock LJ (2014) Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol 9: 1165–1177. doi: 10.2217/fmb.14.66
![]() |
[29] |
Kumar A, Schweizer HP (2005) Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliver Rev 57: 1486–1513. doi: 10.1016/j.addr.2005.04.004
![]() |
[30] |
Lambert PA (2002) Cellular impermeability and uptake of biocides and antibiotics in gram-positive bacteria and mycobacteria. J Appl Microbiol 92: 46S–54S. doi: 10.1046/j.1365-2672.92.5s1.7.x
![]() |
[31] |
Bébéar CM, Pereyre S (2005) Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets 5: 263–271. doi: 10.2174/1568005054880109
![]() |
[32] |
Miller WR, Munita JM, Arias CA (2014) Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti-Infe 12: 1221–1236. doi: 10.1586/14787210.2014.956092
![]() |
[33] | Gill MJ, Simjee S, Al-Hattawi K, et al. (1998) Gonococcal resistance to β-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Ch 42: 2799–2803. |
[34] |
Cornaglia G, Mazzariol A, Fontana R, et al. (1996) Diffusion of carbapenems through the outer membrane of enterobacteriaceae and correlation of their activities with their periplasmic concentrations. Microb Drug Resist 2: 273–276. doi: 10.1089/mdr.1996.2.273
![]() |
[35] |
Chow JW, Shlaes DM (1991) Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J Antimicrob Chemoth 28: 499–504. doi: 10.1093/jac/28.4.499
![]() |
[36] |
Thiolas A, Bornet C, Davin-Régli A, et al. (2004) Resistance to imipenem, cefepime, and cefpirome associated with mutation in Omp36 osmoporin of Enterobacter aerogenes. Biochem Bioph Res Co 317: 851–856. doi: 10.1016/j.bbrc.2004.03.130
![]() |
[37] |
Mah TF (2012) Biofilm-specific antibiotic resistance. Future Microbiol 7: 1061–1072. doi: 10.2217/fmb.12.76
![]() |
[38] |
Soto SM (2013) Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 4: 223–229. doi: 10.4161/viru.23724
![]() |
[39] |
Van Acker H, Van Dijck P, Coenye T (2014) Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol 22: 326–333. doi: 10.1016/j.tim.2014.02.001
![]() |
[40] |
Beceiro A, Tomás M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 26: 185–230. doi: 10.1128/CMR.00059-12
![]() |
[41] |
Randall CP, Mariner KR, Chopra I, et al. (2013) The target of daptomycin is absent form Escherichia coli and other gram-negative pathogens. Antimicrob Agents Ch 57: 637–639. doi: 10.1128/AAC.02005-12
![]() |
[42] |
Yang SJ, Kreiswirth BN, Sakoulas G, et al. (2009) Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200: 1916–1920. doi: 10.1086/648473
![]() |
[43] |
Mishra NN, Bayer AS, Weidenmaier C, et al. (2014) Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 9: e107426. doi: 10.1371/journal.pone.0107426
![]() |
[44] |
Stefani S, Campanile F, Santagati M, et al. (2015) Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents 46: 278–289. doi: 10.1016/j.ijantimicag.2015.05.008
![]() |
[45] | Kumar S, Mukherjee MM, Varela MF (2013) Modulation of bacterial multidrug resistance efflux pumps of the major facilitator superfamily. Int J Bacteriol. |
[46] |
Roberts MC (2003) Tetracycline therapy: update. Clin Infect Dis 36: 462–467. doi: 10.1086/367622
![]() |
[47] |
Roberts MC (2004) Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics. Mol Biotechnol 28: 47–62. doi: 10.1385/MB:28:1:47
![]() |
[48] | Hawkey PM (2003) Mechanisms of quinolone action and microbial response. J Antimicrob Chemoth 1: 28–35. |
[49] |
Redgrave LS, Sutton SB, Webber MA, et al. (2014) Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 22: 438–445. doi: 10.1016/j.tim.2014.04.007
![]() |
[50] |
Huovinen P, Sundström L, Swedberg G, et al. (1995) Trimethoprim and sulfonamide resistance. Antimicrob Agents Ch 39: 279–289. doi: 10.1128/AAC.39.2.279
![]() |
[51] | Vedantam G, Guay GG, Austria NE, et al. (1998) Characterization of mutations contributing to sulfathiazole resistance in Escherichia coli. Antimicrob Agents Ch 42: 88–93. |
[52] |
Blair JM, Webber MA, Baylay AJ, et al. (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13: 42–51. doi: 10.1038/nrmicro3380
![]() |
[53] |
Ramirez MS, Tolmasky ME (2010) Aminoglycoside modifying enzymes. Drug Resist Update 13: 151–171. doi: 10.1016/j.drup.2010.08.003
![]() |
[54] |
Robicsek A, Strahilevitz J, Jacoby GA, et al. (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12: 83–88. doi: 10.1038/nm1347
![]() |
[55] |
Schwarz S, Kehrenberg C, Doublet B, et al. (2004) Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28: 519–542. doi: 10.1016/j.femsre.2004.04.001
![]() |
[56] |
Pfeifer Y, Cullik A, Witte W (2010) Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 300: 371–379. doi: 10.1016/j.ijmm.2010.04.005
![]() |
[57] | Bush K, Bradford PA (2016) β-Lactams and β-lactamase inhibitors: an overview. CSH Perspect Med 6: a02527. |
[58] |
Bush K, Jacoby GA (2010) Updated functional classification of β-lactamases. Antimicrob Agents Ch 54: 969–976. doi: 10.1128/AAC.01009-09
![]() |
[59] | Schultsz C, Geerlings S (2012) Plasmid-mediated resistance in Enterobacteriaceae. Drugs 72: 1–16. |
[60] |
Bush K (2013) Proliferation and significance of clinically relevant β-lactamases. Ann NY Acad Sci 1277: 84–90. doi: 10.1111/nyas.12023
![]() |
[61] | Reygaert WC (2013) Antimicrobial resistance mechanisms of Staphylococcus aureus, In: Microbial pathogens and strategies for combating them: science, technology and education, Spain: Formatex, 297–310. |
[62] |
Toth M, Antunes NT, Stewart NK, et al. (2016) Class D β-lactamases do exist in Gram-positive bacteria. Nat Chem Biol 12: 9–14. doi: 10.1038/nchembio.1950
![]() |
[63] |
Jacoby GA (2009) AmpC β-lactamases. Clin Microbiol Rev 22: 161–182. doi: 10.1128/CMR.00036-08
![]() |
[64] |
Thomson KS (2010) Extended-spectrum-β-lactamase, AmpC, and carbapenemase issues. J Clin Microbiol 48: 1019–1025. doi: 10.1128/JCM.00219-10
![]() |
[65] |
Lahlaoui H, Khalifa ABH, Mousa MB (2014) Epidemiology of Enterobacteriaceae producing CTX-M type extended spectrum β-lactamase (ESBL). Med Maladies Infect 44: 400–404. doi: 10.1016/j.medmal.2014.03.010
![]() |
[66] |
Bevan ER, Jones AM, Hawkey PM (2017) Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemoth 72: 2145–2155. doi: 10.1093/jac/dkx146
![]() |
[67] | Bajaj P, Singh NS, Virdi JS (2016) Escherichia coli β-lactamases: what really matters. Front Microbiol 7: 417. |
[68] |
Friedman ND, Tomkin E, Carmeli Y (2016) The negative impact of antibiotic resistance. Clin Microbiol Infect 22: 416–422. doi: 10.1016/j.cmi.2015.12.002
![]() |
[69] |
Zhanel GG, Lawson CD, Adam H, et al. (2013) Ceftazidime-Avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73: 159–177. doi: 10.1007/s40265-013-0013-7
![]() |
[70] |
Bush K (2018) Game changers: new β-lactamase inhibitor combinations targeting antibiotic resistance in gram-negative bacteria. ACS Infect Dis 4: 84–87. doi: 10.1021/acsinfecdis.7b00243
![]() |
[71] |
Docquier JD, Mangani S (2018) An update on β-lactamase inhibitor discovery and development. Drug Resist Update 36: 13–29. doi: 10.1016/j.drup.2017.11.002
![]() |
[72] |
Villagra NA, Fuentes JA, Jofré MR, et al. (2012) The carbon source influences the efflux pump-mediated antimicrobial resistance in clinically important Gram-negative bacteria. J Antimicrob Chemoth 67: 921–927. doi: 10.1093/jac/dkr573
![]() |
[73] |
Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19: 382–402. doi: 10.1128/CMR.19.2.382-402.2006
![]() |
[74] |
Poole K (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39: 162–176. doi: 10.1080/07853890701195262
![]() |
[75] |
Tanabe M, Szakonyi G, Brown KA, et al. (2009) The multidrug resistance efflux complex, EmrAB from Escherichia coli forms a dimer in vitro. Biochem Bioph Res Co 380: 338–342. doi: 10.1016/j.bbrc.2009.01.081
![]() |
[76] |
Jo I, Hong S, Lee M, et al. (2017) Stoichiometry and mechanistic implications of the MacAB-TolC tripartite efflux pump. Biochem Bioph Res Co 494: 668–673. doi: 10.1016/j.bbrc.2017.10.102
![]() |
[77] |
Jonas BM, Murray BE, Weinstock GM (2001) Characterization of emeA, a norA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Ch 45: 3574–3579. doi: 10.1128/AAC.45.12.3574-3579.2001
![]() |
[78] |
Truong-Bolduc QC, Dunman PM, Strahilevitz J, et al. (2005) MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 187: 2395–2405. doi: 10.1128/JB.187.7.2395-2405.2005
![]() |
[79] |
Kourtesi C, Ball AR, Huang YY, et al. (2013) Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J 7: 34–52. doi: 10.2174/1874285801307010034
![]() |
[80] |
Costa SS, Viveiros M, Amaral L, et al. (2013) Multidrug efflux pumps in Staphylococcus aureus: an update. Open Microbiol J 7: 59–71. doi: 10.2174/1874285801307010059
![]() |
[81] |
Lubelski J, Konings WN, Driessen AJ (2007) Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev 71: 463–476. doi: 10.1128/MMBR.00001-07
![]() |
[82] |
Putman M, van Veen HW, Konings WN (2000) Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64: 672–693. doi: 10.1128/MMBR.64.4.672-693.2000
![]() |
[83] |
Kuroda T, Tsuchiya T (2009) Multidrug efflux transporters in the MATE family. BBA-Proteins Proteom 1794: 763–768. doi: 10.1016/j.bbapap.2008.11.012
![]() |
[84] |
Rouquette-Loughlin, C, Dunham SA, Kuhn M, et al. (2003) The NorM efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds. J Bacteriol 185: 1101–1106. doi: 10.1128/JB.185.3.1101-1106.2003
![]() |
[85] |
Bay DC, Rommens KL, Turner RJ (2008) Small multidrug resistance proteins: a multidrug transporter family that continues to grow. BBA-Biomembranes 1778: 1814–1838. doi: 10.1016/j.bbamem.2007.08.015
![]() |
[86] |
Yerushalmi H, Lebendiker M, Schuldiner S (1995) EmrE, an Escherichia coli 12-kDa multidrug transporter, exchanges toxic cations and H+ and is soluble in organic solvents. J Biol Chem 270: 6856–6863. doi: 10.1074/jbc.270.12.6856
![]() |
[87] |
Collu F, Cascella M (2013) Multidrug resistance and efflux pumps: insights from molecular dynamics simulations. Curr Top Med Chem 13: 3165–3183. doi: 10.2174/15680266113136660224
![]() |
[88] |
Martinez JL, Sánchez MB, Martinez-Solano L, et al. (2009) Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev 33: 430–449. doi: 10.1111/j.1574-6976.2008.00157.x
![]() |
[89] | Deak D, Outterson K, Powers JH, et al. (2016) Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015. Ann Intern Med 165: 363–372. |
1. | Jian Jin, Jie Feng, iDHS-RGME: Identification of DNase I hypersensitive sites by integrating information on nucleotide composition and physicochemical properties, 2024, 734, 0006291X, 150618, 10.1016/j.bbrc.2024.150618 |
Utility for USE | Utility for PSE | Range | ||
HIV+ | HIV+ | | | |
HIV+ | HIV- | | | |
HIV- | HIV+ | | ||
HIV- | HIV- | |
Term | Definition | Baseline value | Range |
Probability of HIV spread from an | 0.02 | - | |
Initial proportion of | 0.05 | 5% of population | |
Initial proportion of | 0.95 | 95% of population |
Utility for USE | Utility for PSE | Range | ||
HIV+ | HIV+ | | | |
HIV+ | HIV- | | | |
HIV- | HIV+ | | ||
HIV- | HIV- | |
Term | Definition | Baseline value | Range |
Probability of HIV spread from an | 0.02 | - | |
Initial proportion of | 0.05 | 5% of population | |
Initial proportion of | 0.95 | 95% of population |